latest news releases from the newsroom
Port of Houston Authority
PHA Commission Considers Bayport, Security, Environmental Matters
HOUSTON, May 16, 2005 (PRIMEZONE) -- The Port of Houston Authority (PHA) commission will consider several recommendations involving contract awards, bids and proposals, professional services and general administrative and operational matters during its public meeting at 2 p.m. on Monday, May 16, 2005 at the PHA Executive Office Building, located at 111 East Loop North (Exit 29 off Loop 610). Chairman Jim Edmonds will preside over the meeting with Vice Chairman Kase Lawal, Commissioner Steve Phelps, Commissioner Jim Fonteno, Commissioner Jimmy Burke, Commissioner Cheryl Thompson-Draper, and Commissioner Janiece Longoria.
NEON Communications Group, Inc.
Globix to Ring AMEX Opening Bell
NEW YORK, May 16, 2005 (PRIMEZONE) -- Globix Corporation (AMEX:GEX), a leading provider of application, media, IP infrastructure and network services, announced today that the Company will ring the opening bell to commence the day's trading at the American Stock Exchange (AMEX) on Wednesday, May, 18, 2005. Globix common stock began trading on AMEX on April 13, 2005.
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc.: Data from KRX-0401 Single Agent Phase 2 Study in Recurrent Prostate Cancer Presented at the American Society of Clinical Oncology Annual Meeting
NEW YORK, May 16, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that Phase 2 data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida demonstrated the tolerability and potential efficacy of KRX-0401 (perifosine) in the treatment of patients with biochemically recurrent hormone-sensitive prostate cancer (HSPC). This study was conducted by a consortium of cancer centers under the leadership of the University of California, Davis pursuant to a Collaborative Research and Development Agreement (CRADA) between Keryx and the National Cancer Institute. KRX-0401 is a novel, oral, anticancer agent that modulates Akt and several other important signal transduction pathways, including MAP kinase and JNK.
Quest Oil Arranges $750,000 Funding for Acadia Gas Project
ARLINGTON, Texas, May 16, 2005 (PRIMEZONE) -- Quest Oil Corporation (OTCBB:QOIL), is pleased to announce that the Company has engaged the services of Midtown Capital Partners Co., LLC to negotiate and secure a $750,000 financing to forward its Acadia gas projects. Upon closing definitive agreements, the Company will announce terms and conditions of the transaction through 8K filing.
SmallCapReview Introduces Resolve Staffing
CHARLOTTE, N.C., May 16, 2005 (PRIMEZONE) -- SmallCapReview.com (www.SmallCapReview.com ), a leading small-cap stock information site, introduces Resolve Staffing (OTCBB:RSFF) to its database of subscribers and its Web site audience.